#	Pagina
attuale pagina	/open-fp7/projects/109607/index.html

MULTISYN

Multimodal Imaging of rare Synucleinopathies

Coordinatore	EBERHARD KARLS UNIVERSITAET TUEBINGEN Organization address address: GESCHWISTER-SCHOLL-PLATZ city: TUEBINGEN postcode: 72074 contact info Titolo: Dr. Nome: Holm Cognome: Graessner Email: send email Telefono: +49 70712985944 Fax: +49 70712925061
Nazionalità Coordinatore	Germany [DE]
Totale costo	7˙865˙514 €
EC contributo	5˙999˙998 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2013-INNOVATION-1
Funding Scheme	CP-FP
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-10-01 - 2018-09-30

Partecipanti

#	participant	country	role	EC contrib. [€]
1	EBERHARD KARLS UNIVERSITAET TUEBINGEN Organization address address: GESCHWISTER-SCHOLL-PLATZ city: TUEBINGEN postcode: 72074 contact info Titolo: Dr. Nome: Holm Cognome: Graessner Email: send email Telefono: +49 70712985944 Fax: +49 70712925061	DE (TUEBINGEN)	coordinator	2˙184˙148.15
2	LUNDS UNIVERSITET Organization address address: Paradisgatan 5c city: LUND postcode: 22100 contact info Titolo: Prof. Nome: Deniz Cognome: Kirik Email: send email Telefono: +46 2220564 Fax: +46 2223436	SE (LUND)	participant	848˙451.00
3	MODAG GmbH Organization address address: MIKROFORUM RING 3 city: WENDELSHEIM postcode: 55234 contact info Titolo: Prof. Nome: Christian Cognome: Griesinger Email: send email Telefono: +49 551 2012201 Fax: +49 551 2012202	DE (WENDELSHEIM)	participant	784˙999.60
4	AFFIRIS AG Organization address address: KARL FARKAS GASSE 22 city: WIEN postcode: 1030 contact info Titolo: Prof. Nome: Achim Cognome: Schneeberger Email: send email Telefono: +43 17981575300 Fax: +43 17981575311	AT (WIEN)	participant	702˙249.25
5	MEDIZINISCHE UNIVERSITAET INNSBRUCK Organization address address: Christoph-Probst Platz 1 city: INNSBRUCK postcode: 6020 contact info Titolo: Dr. Nome: Wolfram Cognome: Rieneck Email: send email Telefono: 43512900000000 Fax: 43512900000000	AT (INNSBRUCK)	participant	537˙410.00
6	PMOD TECHNOLOGIES GMBH Organization address address: RUTISTRASSE 20A city: ADLISWIL postcode: 8134 contact info Titolo: Dr. Nome: Cyrill Cognome: Burger Email: send email Telefono: +41 443504600 Fax: +41 443504601	CH (ADLISWIL)	participant	378˙500.00
7	AARHUS UNIVERSITET Organization address address: Nordre Ringgade 1 city: AARHUS C postcode: 8000 contact info Titolo: Mr. Nome: Thomas Cognome: Tandskov Dissing Email: send email Telefono: +45 23357522	DK (AARHUS C)	participant	321˙240.00
8	"BIOMEDICAL RESEARCH FOUNDATION, ACADEMY OF ATHENS" Organization address address: Soranou Efesiou 4 city: ATHENS postcode: 11527 contact info Titolo: Mr. Nome: Dimitrios Cognome: Raptis Email: send email Telefono: +30 2106597574 Fax: +30 2106597571	EL (ATHENS)	participant	243˙000.00

Mappa

Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

syn aggregation pathogenesis ligand pet protein multimodal diseases therapeutic trials alpha animal synuclein treatment neuroimaging caused misfolded causative clinical functional imaging mri structural ndd molecular models algorithm disease progress

Obiettivo del progetto (Objective)

'Despite remarkable progress in the understanding of the molecular pathogenesis of neurodegenerative diseases (NDD), no causative or disease-modifying treatment is currently available. Aggregation of misfolded proteins are thought to play a crucial role in the pathogenesis, but attempts to exploit this knowledge for novel treatments have not been successful. Also, pathogenetically relevant biomarkers of protein aggregation are lacking. In order to overcome this critical road-block, we have assembled an interdisciplinary consortium, consisting of world-leading experts in structural biology and ligand development, multimodal neuroimaging, animal models and clinical trials to develop a novel imaging system for combined simultaneous molecular and functional imaging (PET-MRI/fMRI) for two rare diseases caused by excessive accumulation of misfolded alpha-synuclein (αSYN), multiple systems atrophy (MSA) and parkinsonism caused by mutations in the alpha-synuclein gene (SNCA), which will serve as proof-of-principle models for the more common and heterogeneous NDD. With this technology we will pioneer the monitoring of protein aggregation as a biomarker for therapeutic effects in the framework of individualized causative treatment. The central aspects of the work-flow including ligand design, software development and drug trials will be driven by three highly specialized SMEs, while translation to animal models and clinical use will be implemented by top academic centers. The groundbreaking progress will include: 1. Establish a multimodal imaging algorithm based on a new PET tracer and embracing structural and functional MRI methods to yield an αSYN specific tool 2. Test this multimodal, molecular neuroimaging algorithm in animal models with regard to its potential for diagnosis, mirroring the natural disease course and response to therapy 3. Translate the algorithm including the therapeutic modality (i.e. immunotherapy with PD01, NCT01568099) to the clinical setting.'